ATE178097T1 - Monoklonale antikörper gegen den alpha-pdgf- rezeptor und deren verwendungen - Google Patents

Monoklonale antikörper gegen den alpha-pdgf- rezeptor und deren verwendungen

Info

Publication number
ATE178097T1
ATE178097T1 AT94921345T AT94921345T ATE178097T1 AT E178097 T1 ATE178097 T1 AT E178097T1 AT 94921345 T AT94921345 T AT 94921345T AT 94921345 T AT94921345 T AT 94921345T AT E178097 T1 ATE178097 T1 AT E178097T1
Authority
AT
Austria
Prior art keywords
alpha
monoclonal antibodies
pdgfr
pdgf
receptor
Prior art date
Application number
AT94921345T
Other languages
English (en)
Inventor
William J Larochelle
Jacalyn Pierce
Roy A Jensen
Stuart A Aaronson
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22162809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE178097(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE178097T1 publication Critical patent/ATE178097T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/49—Platelet-derived growth factor [PDGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT94921345T 1993-06-25 1994-06-24 Monoklonale antikörper gegen den alpha-pdgf- rezeptor und deren verwendungen ATE178097T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/081,216 US5468468A (en) 1989-02-09 1993-06-25 Method for making a monoclonal antibody, monoclonal antibodies to α PD

Publications (1)

Publication Number Publication Date
ATE178097T1 true ATE178097T1 (de) 1999-04-15

Family

ID=22162809

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94921345T ATE178097T1 (de) 1993-06-25 1994-06-24 Monoklonale antikörper gegen den alpha-pdgf- rezeptor und deren verwendungen

Country Status (8)

Country Link
US (3) US5468468A (de)
EP (1) EP0705346B1 (de)
JP (1) JPH08511940A (de)
AT (1) ATE178097T1 (de)
AU (1) AU679247B2 (de)
CA (1) CA2165797A1 (de)
DE (1) DE69417417D1 (de)
WO (1) WO1995000659A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228600B1 (en) 1992-07-20 2001-05-08 The United States Of America As Represented By The Department Of Health And Human Services Immunoassays for the alpha platelet-derived growth factor receptor
US7252929B2 (en) 1989-02-09 2007-08-07 United States Of America, As Represented By The Secretary, Dept Of Health & Human Services Methods for identifying alpha PDGFR agonists and antagonists
US5817310A (en) 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US20020044933A1 (en) * 1993-02-25 2002-04-18 Hart Charles E. Inhibition of intimal hyperplasia using antibodies to PDGF receptors
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US5882644A (en) * 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US6416960B1 (en) 1996-08-08 2002-07-09 Prolume, Ltd. Detection and visualization of neoplastic tissues and other tissues
DE19652374A1 (de) * 1996-12-04 1998-06-10 Schering Ag Verwendung von Endothelin-Konjugaten in der Therapie, neue Endothelin-Konjugate, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
US7381525B1 (en) 1997-03-07 2008-06-03 Clinical Micro Sensors, Inc. AC/DC voltage apparatus for detection of nucleic acids
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
WO1998051350A1 (en) * 1997-05-12 1998-11-19 Dana-Farber Cancer Institute Methods of treatment using nbs-1, antibodies and proteins thereto, and uses of the antibodies
US6264949B1 (en) * 1998-09-29 2001-07-24 Mount Sinai School Of Medicine Of New York University Noninvasive agents for diagnosis and prognosis of the progression of fibrosis
US7425541B2 (en) * 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
AUPQ661800A0 (en) * 2000-03-31 2000-05-04 Metabolic Pharmaceuticals Limited Insulin-potentiating compounds
NZ553470A (en) 2002-03-15 2008-10-31 Schering Corp Methods of modulating CD200 receptors
US20040171034A1 (en) * 2002-05-03 2004-09-02 Brian Agnew Compositions and methods for detection and isolation of phosphorylated molecules
CA2488876A1 (en) * 2002-06-13 2003-12-24 Oregon Health & Science University Activating mutations of platelet derived growth factor receptor alpha (pdgfra) as diagnostic markers and therapeutic targets
US7144864B2 (en) * 2002-09-25 2006-12-05 Hidechika Okada Carboxypeptidase R inhibiting peptide
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
CA2580644A1 (en) * 2004-09-17 2006-03-30 University Of Utah Research Foundation Imaging reporters of transgene expression
CA2612449A1 (en) * 2005-06-17 2006-12-28 Imclone Systems Incorporated Receptor antagonists for treatment of metastatic bone cancer
DE602006019262D1 (de) * 2005-08-11 2011-02-10 Siemens Healthcare Diagnostics QUANTITATIVE ASSAYS FÜR PDGFR-beta- IN KÖRPERFLÜSSIGKEITEN
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
WO2008093246A2 (en) 2007-02-02 2008-08-07 Vegenics Limited Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
BR112012033457A2 (pt) 2010-07-02 2017-04-04 Medimmune Llc formulações de anticorpo.
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
RU2014140116A (ru) 2012-04-24 2016-06-10 Тромбодженикс Н.В. Антитела против pdgf-c
HK1220465A1 (zh) 2013-03-06 2017-05-05 Merrimack Pharmaceuticals, Inc. 抗c-met串联fc双特异性抗体
DE102015008050A1 (de) 2015-06-19 2016-12-22 Technische Universität Ilmenau Anordnung in Form eines Modellsystems zur Nachbildung von maternalen und fetalen Pulskurven für die nichtinvasive transabdominale Plethysmografie
WO2017035315A1 (en) * 2015-08-27 2017-03-02 The Johns Hopkins University Methods and device for phenotypic classification of cells based on migratory behavior
ES2981791T3 (es) 2015-12-16 2024-10-10 Regeneron Pharma Composiciones y métodos para fabricar micropartículas de proteína
PH12022550646A1 (en) * 2019-09-18 2023-04-03 Genentech Inc Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4699880A (en) * 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US5094941A (en) * 1987-12-31 1992-03-10 Zymogenetics, Inc. Monoclonal antibodies to PDGF
US5268358A (en) * 1988-12-08 1993-12-07 Cor Therapeutics, Inc. PDGF receptor blocking peptides
AU629920B2 (en) * 1989-02-09 1992-10-15 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Type oc platelet-derived growth factor receptor gene
WO1990014425A1 (en) * 1989-05-22 1990-11-29 Zymogenetics, Inc. PDGF α-RECEPTOR
AU675924B2 (en) * 1991-12-02 1997-02-27 Cor Therapeutics, Inc. Methods for production of purified soluble type B and type Ahuman platelet-derived growth factor receptor fragments

Also Published As

Publication number Publication date
EP0705346B1 (de) 1999-03-24
US5468468A (en) 1995-11-21
WO1995000659A1 (en) 1995-01-05
AU7210994A (en) 1995-01-17
JPH08511940A (ja) 1996-12-17
US5863739A (en) 1999-01-26
CA2165797A1 (en) 1995-01-05
EP0705346A1 (de) 1996-04-10
DE69417417D1 (de) 1999-04-29
AU679247B2 (en) 1997-06-26
US5833986A (en) 1998-11-10

Similar Documents

Publication Publication Date Title
ATE178097T1 (de) Monoklonale antikörper gegen den alpha-pdgf- rezeptor und deren verwendungen
ES2548327T3 (es) Método para detectar proBNP con un anticuerpo monoclonal
IL149062A0 (en) Improved method for detecting acid resistant microorganisms in the stool
DK261386A (da) Monoklonale antistoffer
ATE395364T1 (de) Gegen procalcitonin gerichtete antikörper, ihre herstellung und verwendung
AU1157100A (en) Detection of acid-resistant micro-organisms in a stool
KR910021585A (ko) 알쯔하이머병의 진단 분석법
KR910016346A (ko) 광견병 바이러스에 대한 사람 모노클로날 항체, 이의 제조방법 및 용도
ATE245169T1 (de) Monoklonale antikörper spezifisch für endprodukte der fortgeschrittenen glycosylation in biologischen proben
EP1908837A3 (de) Menschliche Rezeptorproteine, zugehörige Reagenzien und Verfahren
DE60045870D1 (de) Monoklonaler antikörper, hybridoma, immuntestverfahren und diagnosekit
DE69011613T2 (de) Monoklonaler Antikörper gegen Kern-hCG-beta, seine Herstellung und Verwendung.
DE69018968D1 (de) BLUTGERINNUNGSFAKTOR BETA XIIa MONOKLONALE ANTIKÖRPER UND IMMUNANALYSE.
DE3884731D1 (de) Monoklonaler Antikörper gegen Methamphetamin, seine Herstellung, Testverfahren und Testsatz für Methamphetamin.
DE69504620D1 (de) Monoklonaler Antikörper gegen menschliches Glicentin, Hybridoma zur Herstellung dieses Antikörpers und Testverfahren für menschliches Glicentin unter Verwendung dieses Antikörpers
ATE75754T1 (de) Monoklonale antikoerper gegen atriale, natriurethische peptide.
DE3633323A1 (de) Neue monoklonale antikoerper gegen ifn-omega, verfahren zu ihrer herstellung und deren verwendung zur reinigung sowie zum nachweis von ifn-omega
DE4008546A1 (de) Osteocalcin-spezifischer monoclonaler antikoerper
SE9602234D0 (sv) A novel diagnostic method utilizing ECP, and reagents to be used in the methods
CN106929477B (zh) 一株抗前列腺素F2α的特异性单克隆抗体杂交瘤细胞株WXX-2及其应用
FR2599513B1 (fr) Anticorps monoclonaux inhibant la liaison de ige soluble aux lymphocytes humains, hybridomes monoclonaux produisant de tels anticorps, leur utilisation
ATE293685T1 (de) Monoklonaler antikörper gegen ratte beta-2- integrin alpha d untereinheit und entsprechendes hybridoma
Kuan et al. Detection of amino-terminal extracellular domain of somatostatin receptor 2 by specific monoclonal antibodies and quantification of receptor density in medulloblastoma
Mirowski et al. Immunohistochemical study of 65-kDa oncofetal protein expression in breast cancer
Hayman et al. Soluble human leukocyte antigen: A diagnostic indicator of rheumatoid arthritis?

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties